

The Combination of Neuropsychiatric Symptoms and Blood-based biomarkers for Early Detection of Cognitive Disorders

*The submission is a preprint.

*The paper is under review at Molecular Neurodegeneration.

Yi Jin **Leow** (PGDip)¹, Zahinoor **Ismail** (MD, FRCPC)^{6,7}, Seyed Ehsan **Saffari** (PhD)⁴, Gurveen Kaur **Sandhu**(PhD)¹, Pricilia **Tanoto** (MSc)¹, Faith Phemie Hui En **Lee** (BA)¹, Smriti **Ghildiyal** (BA)¹, Shan Yao **Liew** (BA)¹, Gursimar **Bhalla** (BSc)¹, **Sim** Xin Ying (BSc)¹, Adnan Azam **Mohammed** (BEng)¹, Ashwati **Vipin**(PhD)¹, Chao **Dang** (MD, PhD)⁵, Nagaendran **Kandiah** (MD, FRCP)^{1,2,3,4}

¹*Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore*

²*Neuroscience and Mental Health Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore*

³*National Healthcare Group, Singapore*

⁴*Duke-NUS Medical School, National University of Singapore, Singapore*

⁵*The First Affiliated Hospital, Sun Yat-sen University, China*

⁶*Hotchkiss Brain Institute, University of Calgary, Canada*

⁷*University of Exeter Faculty of Health and Life Sciences and NIHR Exeter Biomedical Research Centre, Exeter UK*

Corresponding Author: Associate Professor Nagaendran Kandiah

Address: Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Rd, Singapore 308232

Tel: 65 65922653

Email: nagaendran_kandiah@ntu.edu.sg

Abstract

Background: Integrating behavioural assessments with blood-based biomarkers (BBM) could improve diagnostic accuracy for Mild Cognitive Impairment (MCI) linked to early-stage neurodegenerative disease (NDD). This study investigates the potential of combining neuropsychiatric symptoms (NPS) with BBM to enhance the differentiation between older adults with MCI and those with Normal Cognition (NC) in a multi-ethnic Southeast Asian cohort.

Methods: This cross-sectional study analyzed baseline data from the Biomarkers and Cognition Study, Singapore (BIOCIS). Data from 678 participants (mean[SD]age 59.16[11.02]years, 39.50% males) with NC and MCI were included. Behavioral symptoms were assessed using the Mild Behavioral Impairment Checklist (MBI-C) and Depression, Anxiety, and Stress Scales (DASS). Blood samples were analyzed for amyloid-beta ($A\beta_{40}$, $A\beta_{42}$), phosphorylated Tau (p-tau181), neurofilament light (NfL) and glial fibrillary acidic protein (GFAP). Regression models adjusted for age, education, gender, cognitive status (CS) and APOE- ϵ 4 status were used. Discriminative power was evaluated using the area under the curve (AUC) to assess the combined predictive accuracy of behavioral and biological markers for CS, i.e., MCI status over CN.

Results: The study included MBI-C scores (total, interest, mood, control) and BBM levels ($A\beta_{40}$, NfL, GFAP) were significantly higher in MCI group, compared to CN group. Elevated GFAP (OR:3.636, 95% CI:1.959, 6.751, $p < 0.001$) and higher MBI-C-Mood scores (OR:2.614, 95% CI:1.538, 4.441, $p < 0.001$) significantly increased the likelihood of MCI. The combined model, integrating NPS and BBM markers, showed strong discriminative ability for MCI (AUC = 0.786), with 64.7% sensitivity and 84.9% specificity at a threshold of 0.616, compared to NPS markers (AUC: 0.593) or BBM (AUC: 0.697) alone.

Conclusions and Relevance: The combined use of BBM and NPS achieved optimal accuracy in distinguishing MCI from NC, with strong associations between GFAP, MBI-C Mood scores, and CS. These findings underscore neuroinflammation and mood disturbances as critical factors in early NDD, supporting the importance of dual-dimension screening strategies. Integrating NPS and BBM represents a novel and effective diagnostic approach for detection of MCI due to AD or other dementias. The integrated framework, leveraging both pathophysiological and neuropsychiatric markers, facilitates earlier diagnosis, potentially improving clinical decision-making and enabling targeted disease-modifying therapies for individuals with neurodegenerative disorders.

Keywords: mild behavioral impairment, neurodegenerative disorders, mild cognitive impairment

Background

With the advancement of dementia treatments comes the responsibility to leverage biomarkers to identify cognitive impairment secondary to neurodegenerative disease (NDD) accurately at earlier stages. Plasma-derived and behavioural-biomarkers could play a crucial role for the early detection of NDD-related cognitive impairment, offering both accessibility and a holistic perspective on mechanistic and pathological changes, as well as observable symptoms, that occur during the onset of cognitive decline (CD). Current research demonstrates the value of blood-based biomarkers (BBM) in detection of NDD, enhancing traditional assessment tools such as neuropsychological assessments, positron emission tomography (PET) scans and neuroimaging.

The integration of behavioral-biomarkers—especially those reflecting mood and personality changes—can add significant diagnostic precision for Alzheimer’s disease (AD) and related dementias. Neuropsychiatric symptoms (NPS) are non-cognitive, behavioral, or psychiatric symptoms that often accompany or precede CD (1). A notable subset of NPS is Mild Behavioral Impairment (MBI), characterized by the later-life onset of persistent behavioral symptoms that represent change from baseline, which has emerged as a reliable predictor of CD and incident dementia (2–4). The Mild Behavioral Impairment Checklist (MBI-C) was developed explicitly to measure MBI, and comprises five domains including decreased motivation, emotional dysregulation, impulse dyscontrol, social inappropriateness, and abnormal perception or thoughts (5). Current research demonstrates that the MBI-C effectively distinguishes NPS linked to NDD from NPS related to psychiatric or stress-related etiologies, thereby enhancing dementia risk assessment (6–8). Complementarily, the Depression, Anxiety, and Stress Scales (DASS) (9) provide a comprehensive evaluation of mood symptoms in dementia increasingly recognized as early indicators of CD (10,11). Together, the MBI-C and DASS offer a holistic approach, capturing a broad spectrum of behavioural and psychological changes that correlates with cerebrospinal fluid (CSF) (12), plasma biomarkers (13,14), and cognitive impairment (15,16).

In parallel with behavioral assessments, BBM are transforming AD diagnosis by providing a minimally invasive and accessible alternative to traditional CSF and PET biomarkers (17–21). Recent research shows that BBM achieve high accuracy in predicting clinical decline in individuals with mild cognitive impairment (MCI), highlighting their potential as early indicators (22,23). A Swedish study confirmed that BBM targeting amyloid-beta and phosphorylated tau achieve diagnostic accuracy comparable to CSF and PET, with predictive values exceeding 90%, demonstrating their clinical utility in various care settings (24). Compared to CSF biomarkers, BBM offer significant practical advantages as they are highly scalable, less invasive and promote higher patient compliance. BBM are therefore more feasible for large-scale screening and triage in under-resourced settings, while facilitating the integration of anti-amyloid therapies into routine clinical practice (25).

Within the Amyloid, Tau, and Neurodegeneration(ATN) framework, amyloid-beta 42(A β 42), amyloid-beta 40(A β 40), and the A β 42/A β 40 ratio are key markers of amyloid plaque accumulation, a defining feature of AD pathology(26,27). For tau pathology, phosphorylated Tau 181(p-tau181) serves as a marker for neurofibrillary tangles associated with AD progression (28–30). Additionally, Neurofilament light(NfL) provides insights into neuroaxonal damage, while Glial fibrillary acidic protein (GFAP) is associated with reactive astrogliosis and neuroinflammation(31–33). Alongside these ATN biomarkers, genetic factors such as Apolipoprotein E ϵ 4(APOE4) genotype play a critical role in AD risk and biomarker expression. APOE4 is strongly linked to increased amyloid-beta accumulation and is one of the most significant genetic risk factors for late-onset AD. Notably, populations in Southeast Asia exhibit a lower prevalence of APOE4 compared to Western populations (34), potentially explaining differences in amyloid positivity, CD rates, and dementia types observed between these groups (35). Recently, the European Medicines Agency, stipulated that lecanemab could not be prescribed in APOE4 homozygotes, further supporting its importance (36). Together, these BBM and blood-based genetic factors provide a multifaceted view of neurodegeneration, offering deeper insights into CD and AD risk and progression.

Given the capacity to capture diverse aspects of neurodegeneration, BBM hold significant potential for elucidating the relationship between behavioral symptoms and the progression of NDD. The link between NPS and BBMs is still emerging, with research to date yielding mixed results. For instance, in a large population-based study, no difference in AD risk was observed between APOE4 carriers and non-carriers among Americans without baseline depression(37). For amyloid-related biomarkers, amyloid-beta has been more extensively studied in relation to behavioral symptoms, particularly depression(38). A study in Vienna reported that higher baseline plasma A β 42 levels predicted incident depression and conversion to AD over five years(39). Similarly, the Rotterdam Study reported cross-sectional links between high A β 40 and depressive symptoms in prodromal dementia, but longitudinally associated lower A β 40 and A β 42 with increased depression risk in elderly individuals without dementia, indicating a complex role of A β peptides in the etiology of depression(40). For tau biomarkers, elevated plasma p-tau181 has been associated with NPS such as appetite changes and disinhibition(41). Regarding neurodegeneration biomarkers, NfL has shown promise as a marker for multiple NPS, including aberrant motor behavior, anxiety, sleep disturbances and euphoria(42). GFAP, another marker of neurodegeneration, has been associated with depression(43).

Focusing on MBI, characterized by late-life emergent and persistent NPS, findings consistently link it to key BBM in the ATN framework. For amyloid-related biomarkers, global MBI status and MBI affective dysregulation demonstrated associations with amyloid-beta(44). In terms of tau pathology, recent findings by Ghahremani(13) indicate MBI correlates with elevated plasma p-

tau181 levels and a nearly fourfold increased risk of dementia, with higher baseline and longitudinal increases in p-tau181 in individuals with MBI compared to those without MBI. Additionally, Gonzalez-Bautista(14) linked MBI domains, such as impulse dyscontrol and emotional dysregulation, to p-tau181 and metabolic biomarkers, implicating tau alongside metabolic disruption in preclinical and prodromal AD. In neurodegeneration, findings from the Alzheimer's Disease Neuroimaging Initiative(ADNI) cohort revealed that in preclinical and prodromal samples, MBI and its interaction with time predict NfL changes, indicating MBI as an early marker of accelerated neurodegeneration and CD(45). Collectively, these studies illustrates MBI's value as an early marker of AD pathology and dementia risk.

The growing research on BBM, MBI, and NPS at early stages of CD underscores their potential for early disease detection. When combined, these markers offer a multifaceted approach to early diagnosis, capturing both pathobiological and psychological dimensions of dementia onset. Despite this prospect, a comprehensive study systematically combining these markers for detecting cognitive impairment has, to our knowledge, not yet been conducted.

This study evaluates the predictive utility of BBM and behavioral-biomarkers in distinguishing persons with MCI from those with normal cognition. By systematically analyzing MBI-C, DASS and BBM in a multi-ethnic Southeast Asian cohort, we assess the combined value of these measures for higher diagnostic accuracy for MCI linked to NDD and to explore underlying mechanisms of cognitive impairment.

Methods

Participants

Participants were drawn from the Biomarkers and Cognition Study, Singapore(BIOCIS), a 5-year longitudinal study with annual assessments. Recruitment is community-based, targeting individuals aged 30 to 95 years in Singapore. To explore how pathology presents with or without minimal clinical symptoms, both cognitively impaired and unimpaired individuals are included. Participants were classified as Cognitively Normal(CN) or as having MCI based on Peterson's(46) criteria and National Institute on Aging-Alzheimer's Association(NIA-AA) guidelines(47) after completion of a validated neuropsychological test battery. Further study design and methodological details are available in the BIOCIS protocol paper(48).

Blood based biomarkers

Venepuncture was performed by a certified phlebotomist at baseline study visit. Blood samples were collected in EDTA vacutainers, left at room temperature for 30 minutes, then centrifuged at 2000 g for 10 minutes at 4°C. The resulting plasma was aliquoted and stored at -80°C. Genomic DNA was extracted from whole blood samples, collected into EDTA vacutainers(Becton Dickinson) using the QIAamp DNA Blood Maxi Kit(Qiagen). The concentration and purity of the DNA were assessed using a Nanodrop One spectrophotometer (Thermo Fisher Scientific, United Kingdom). DNA was analysed using either the StepOne plus or QuantStudio 7 Pro Real-Time Polymerase Chain Reaction analyser(Applied Biosystems) to determine the allelic variants of APOE. APOE genotypes were determined using SNPs rs429358 and rs7412(Life Technologies), as per manufacturer's protocol, using a 96-well MicroAmp Fast(StepOne Plus)/Optical(Quantstudio) reaction plate(Life Technologies), with 10ng of DNA and either one of the 2 SNPs, in a 10ul TaqPath ProAmp master mix reaction(Applied Biosystems)(49,50). Results were analysed using the Design and Analysis 2.5.1 Real Time PCR system software(Applied Biosystems) and respective APOE genotype were rated independently by raters. Quanterix's Single Molecule Array(Simoa) digital biomarker technology platform was used to quantify all plasma biomarkers(NfL, GFAP, A β 40, A β 42, p-tau181)(Quanterix, Billerica, MA, USA). The Neurology 4-PlexE(NfL, GFAP, A β 40, A β 42) and p-tau181 Advantage V2.1 kits were utilized for expression analysis on the HD-X Analyzer platform(Quanterix, Billerica, MA, USA) in accordance with manufacturer's protocol(51).

Behavioural profiles and Neuropsychiatric symptoms

Self-reported questionnaires were administered including MBI-C and DASS. The MBI-C(5) evaluates MBI across five NPS domains: Mood/Anxiety, Apathy/Drive, Impulse Dyscontrol, Social Inappropriateness, and Abnormal Perception/Thought Content, with symptoms required to persist for at least six months and represent a change from longstanding baseline. The DASS(9) assesses depression, anxiety, and stress over a one-week timeframe.

Statistical Analyses

Continuous variables were summarized using mean and standard deviation, while categorical variables were described using frequency and percentages. To address skewness, logarithmic transformations were applied to blood and behavioral data, with a constant of 1 added to continuous variables that included values below 1. Two independent sample t tests were employed to compare continuous variables between the CN and MCI groups. Categorical variables were compared between CN and MCI using Chi-square test.

Logistic regression models were performed to investigate the association of baseline characteristics and cognitive diagnosis(MCI vs CN) while adjusting for age, years of education, gender and APOE status. The results were reported as odds ratio(OR), 95% confidence interval(CI), and p value. A dual-regression approach was implemented, consisting of two multivariable logistic regression models with cognitive status(MCI vs CN) as outcome. The first regression(Model 1), included behavioral parameters only as continuous variable predictors and the second(Model 2) included BBM only as continuous variables, both adjusted for demographic variables and APOE status. Within each model, a backward variable selection approach identified variables independently associated with cognitive diagnosis. Subsequently, the shortlisted variables from both models were included in a final multivariable logistic regression model(Combined Model), adjusted for demographic variables and APOE status. Further, overall discriminative power of the final model was assessed via area under the curve(AUC) analyses with model performance evaluated using Hosmer and Lemeshow lack-of-fit test. For all models, variance inflation factor statistics and independence of errors were utilized to confirm the absence of multi-collinearity among predictor variables.

To further understand the association between behavioral parameters, cognitive diagnoses, and BBM, additional logistic regressions were implemented. Predictors were behavioural-biomarkers as continuous variables, adjusting for demographics, APOE status, and cognitive diagnosis (Model 4). Outcomes were blood biomarker status(i.e., high vs low), based on dichotomization using a median split (52,53).

All statistical analyses were conducted using IBM SPSS Statistics, Version 29.0(Armonk,NY:IBM Corp.), with statistical significance set as $p < 0.05$ unless otherwise specified.

Results

Demographics

678 participants were recruited. The MCI group was older ($p < .001$) and had fewer years of education ($p < .001$). For behavioral assessments, MBI-C-Total scores were higher in the MCI group ($p = 0.006$), with significant differences in the interest ($p = 0.005$), mood ($p = 0.005$), and control ($p = 0.009$) subdomains. Additionally, BBM analyses showed higher mean levels of A β 40 ($p < 0.001$), NfL ($p < 0.001$), and GFAP ($p < 0.001$) in the MCI group compared to the CN. Table 1 summarizes the BIOCIS demographic variables alongside behavioral and BBM data.

Table 1. Participant demographics, behavioural phenotype, and blood biomarker levels by cognitive diagnosis

Variable	Total Cohort (n=678)	Cognitively Normal (n=334)	Mild Cognitive Impairment (n=344)	p-value*
Demographics				
Age (year) †	59.16 ± 11.02	54.89 ± 10.24	63.31 ± 10.14	< 0.001
Gender (male) □	267 (39.50%)	126 (38.00%)	141 (41.00%)	0.432
Education (years) †	14.76 ± 3.69	15.77 ± 3.33	13.78 ± 3.76	< 0.001
Presence of APOE ϵ 4 □	119 (17.70%)	54 (16.20%)	65 (19.00%)	0.471
Mild Behavioural Impairment-Checklist				
Total †	2.18 ± 5.22	1.63 ± 3.66	2.73 ± 6.36	0.006
Interest †	0.42 ± 1.30	0.28 ± 0.86	0.56 ± 1.61	0.005
Mood †	0.60 ± 1.56	0.43 ± 1.26	0.76 ± 1.79	0.005
Control †	0.72 ± 1.64	0.55 ± 1.22	0.89 ± 1.95	0.009
Social †	0.20 ± 0.63	0.19 ± 0.58	0.21 ± 0.68	0.616
Beliefs †	0.24 ± 3.08	0.17 ± 2.19	0.30 ± 3.75	0.587
Depression Anxiety Stress Scales				
Depression †	3.41 ± 4.63	2.92 ± 4.23	3.88 ± 4.94	0.007
Anxiety †	4.00 ± 4.19	3.78 ± 4.08	4.22 ± 4.30	0.174
Stress †	6.31 ± 5.92	6.21 ± 5.74	6.40 ± 6.10	0.671
Blood biomarker				
A β 42 (pg/mL) †	5.22 ± 2.27	5.10 ± 1.91	5.34 ± 2.57	0.167

Aβ40 (pg/mL)†	78.76 \pm 24.81	74.68 \pm 23.28	82.73 \pm 25.63	< 0.001
Aβ42/40 (ratio)†	0.0672 \pm 0.0241	0.0687 \pm 0.0201	0.0658 \pm 0.0274	0.110
p-tau181 (pg/mL)†	18.67 \pm 10.13	18.15 \pm 11.86	19.16 \pm 8.08	0.194
p-tau181/Aβ42 (ratio)†	4.23 \pm 3.13	4.19 \pm 3.54	4.26 \pm 2.69	0.780
NfL (pg/mL)†	14.45 \pm 8.73	12.18 \pm 6.96	16.66 \pm 9.67	< 0.001
GFAP (pg/mL)†	84.90 \pm 44.38	71.41 \pm 32.29	98.00 \pm 50.26	< 0.001

Note. † = mean \pm Standard Deviation, □ = Frequency (percentages)

* Comparing the two groups using two-independent sample t-test (or Mann-Whitney U test, depends on normality) for continuous variables or Chi-square (or Fisher's exact test, where appropriate) for categorical variables

Abbreviations: APOE = Apolipoprotein E, A β = Amyloid Peptides, p-tau181 = Phosphorylated Tau at position 181, GFAP = Glial fibrillary acidic protein, NfL =Neurofilament Light Chain

Behavioral and BBM as Independent Predictors of MCI Over CN

Table 2 summarizes the results of the multivariable logistic regression analyses, detailing significant behavioral and blood-based predictors of MCI over CN. In the behavioural model(Model 1), for each 1-point increase in the MBI-C-Mood subdomain, the odds of having MCI over being CN increased by approximately 59%(OR:1.587, 95%CI: 1.127–2.236, p=0.008). Similarly, for each 1-point increase in the DASS Depression score, the odds of MCI over CN increased by 25%(OR:1.250, 95%CI: 1.013–1.542, p=0.037). In contrast, higher DASS-Stress scores were inversely associated with cognitive impairment, with each 1-point increase in DASS-Stress reducing the odds of MCI by 20%(OR:0.800, 95%CI: 0.660–0.970, p=0.023). The AUC for behavioral-markers alone was 0.593(95%CI: 0.55–0.636).

Among BBM(Model 2), elevated NfL and GFAP levels were strongly associated with the likelihood of being classified as MCI over CN. Each unit increase in NfL corresponded to a 110% increase in MCI likelihood over CN(OR:2.096, 95% CI: 1.365–3.217, p=0.001). GFAP showed an even stronger association, with each unit increase raising the odds of MCI over CN by approximately 199%(OR:2.987, 95%CI: 1.913–4.664, p<0.001).

Table 2. Multivariable Logistic Regression Analysis of Key Behavioral and Blood Biomarkers as Predictors of Cognitive Diagnosis

Variable	Odds Ratio	95% CI	p-value
Model 1 - Behavioural Biomarker			
MBI-C-Mood	1.587	(1.127, 2.236)	0.008
DASS-Depression	1.250	(1.013, 1.542)	0.037
DASS-Stress	0.800	(0.660, 0.970)	0.023
Model 2 - Blood Biomarker			
NfL	2.096	(1.365, 3.217)	0.001
GFAP	2.987	(1.913, 4.664)	<0.001

Abbreviations: MBI-C = Mild Behavioural Impairment-Checklist, DASS = Depression Anxiety Stress Scales, NfL =Neurofilament Light Chain, GFAP = Glial fibrillary acidic protein

Combined Model of Predictive Value of Behavioral Scores and Blood Biomarker Levels for Cognitive Status

In the behavioural and blood model(Combined Model), variables from Table 2(i.e.,variables from the Model 1 and 2 meeting statistical significance) were included along with demographics and APOE status as clinical confounders. Higher GFAP(OR:3.636, 95%CI: 1.959–6.751, $p < 0.001$) and MBI-C-Mood(OR:2.614, 95%CI: 1.538–4.441, $p < 0.001$) significantly increased the likelihood of MCI by 263.6% and 161.4% respectively. The model AUC was 0.786(95%CI: 0.744–0.827), surpassing separate models based on either behavioral-markers(AUC:0.593, 95%CI: 0.55–0.636) or BBM(AUC:0.697, 95%CI: 0.658–0.736). At an optimal threshold of 0.616, the Combined model achieved 64.7% sensitivity and 84.9% specificity, demonstrating strong discriminatory ability in distinguishing between CN and MCI individuals(Figure 1).




Figure 1. Receiver Operating Characteristic (ROC) Curves Comparing Different Models for Distinguishing Between Cognitively Normal and Mild Cognitive Impairment Groups

Behavioural and Cognitive Diagnoses in Association with Dichotomized BBM Levels

For Model 4, with continuous behaviour scores as predictors and biomarker status as binary outcome, a higher MBI-C-Total score was significantly associated with odds of high A β 42 status (OR:1.437, 95% CI: 1.127–1.831, $p=0.003$). Specific MBI-C subdomains were significantly linked to likelihood of high A β 42: MBI-C-Interest (OR:1.800, 95% CI: 1.139–2.845, $p=0.012$), MBI-C-Mood (OR:1.587, 95% CI: 1.068–2.359, $p=0.022$), and MBI-C-Control (OR:1.782, 95% CI: 1.242–2.557, $p=0.002$). Higher DASS-Stress scores were significantly associated with likelihood of high A β 40 levels (OR:1.252, 95% CI: 1.039–1.508, $p=0.018$). MBI-C-Total score was associated with likelihood of high p-tau181 (OR:1.279, 95% CI: 1.001–1.634, $p=0.049$). Additionally, higher DASS-Depression scores (OR:1.302, 95% CI: 1.061–1.598, $p=0.012$) and higher DASS-Stress scores (OR:1.238, 95% CI: 1.020–1.503, $p=0.031$) significantly increased the odds of high p-tau181. Lastly, higher DASS-Anxiety scores were marginally associated with probability of high GFAP levels (OR:1.260, 95% CI: 1.000–1.587, $p=0.05$). Table 3 presents a detailed summary of these results.

Table 3. Multivariate Logistic Regression Analysis of Behavioral-Biomarkers in Relation to Blood Biomarkers

Variable	A β 42	A β 40	A β 42/40	p-tau181	p-tau181/A β 42	Nf-L	GFAP
MBI-C Total	1.44 (1.13, 1.83)**	1.16 (0.92, 1.47)	1.15 (0.86, 1.53)	1.28 (1.001, 1.63)*	0.84 (0.66, 1.07)	0.83 (0.62, 1.12) [†]	1.08 (0.83, 1.39)
MBI-C Interest	1.8 (1.14, 2.85)*	1.34 (0.87, 2.06)	1.21 (0.72, 2.02)	1.34 (0.86, 2.07)	0.78 (0.51, 1.20)	0.69 (0.40, 1.20)	1.16 (0.74, 1.83)
MBI-C Mood	1.59 (1.07, 2.36)*	1.21 (0.82, 1.77)	1.43 (0.87, 2.34)	1.27 (0.85, 1.89)	0.82 (0.55, 1.20)	0.84 (0.52, 1.37)	1.32 (0.87, 1.99)
MBI-C Control	1.78 (1.24, 2.56)**	1.34 (0.95, 1.88)	1.11 (0.74, 1.67)	1.37 (0.97, 1.94)	0.79 (0.56, 1.12)	0.84 (0.55, 1.28)	1.05 (0.73, 1.52)
MBI-C Social	1.45 (0.68, 3.09)	1.37 (0.64, 2.90)	1.16 (0.46, 2.92)	1.45 (0.66, 3.16)	0.93 (0.44, 1.99)	0.87 (0.34, 2.25)	0.90 (0.40, 2.01)
MBI-C Beliefs	0.68 (0.20, 2.26)	0.76 (0.22, 2.64)	3.01 (0.38, 23.6)	3.34 (0.91, 12.3)	1.26 (0.37, 4.35)	0.46 (0.08, 2.52)	0.97 (0.26, 3.67)
DASS Depression	1.09 (0.90, 1.32)	1.22 (<1, 1.48)	1.18 (0.94, 1.50)	1.30 (1.06, 1.60)*	0.97 (0.80, 1.18)	0.83 (0.65, 1.06)	1.09 (0.88, 1.35)
DASS Anxiety	1.17 (0.95, 1.44)	1.23 (<1, 1.52)	0.98 (0.76, 1.25)	1.13 (0.91, 1.41)	0.95 (0.77, 1.17)	0.93 (0.72, 1.20)	1.26 (<1, 1.59)
DASS Stress	1.20 (1.004, 1.45)*	1.25 (1.04, 1.51)*	1.01 (0.81, 1.26)	1.24 (1.02, 1.50)*	0.98 (0.81, 1.18)	1.07 (0.86, 1.34)	1.04 (0.85, 1.27)

Abbreviations: MBI-C = Mild Behavioural Impairment-Checklist, DASS = Depression Anxiety Stress Scales, p-tau181 = Phosphorylated Tau at position 181, NfL = Neurofilament Light Chain A β = Amyloid Peptides, GFAP = Glial fibrillary acidic protein

[†] Odds ratio (95% CI), * p<0.05, ** p<0.005, significant p values are bolded.

Discussion

Integration of Biomarkers for Early Detection of Cognitive Impairment

The results demonstrate that integrating blood-based and behavioral measures enhances prediction of MCI status compared to using either measure alone. Specifically, models that combine both BBM and behavioral data demonstrate the highest accuracy in identifying MCI status, with BBM alone outperforming behavioral measures when used in isolation. These findings present three key insights: behavioral measures contribute to cognitive status prediction and correlate with BBM, BBM alone serve as robust predictors of MCI, and the combined model provides superior predictive power over individual approaches.

Behavioural-biomarkers as Indicators of MCI status

Higher scores on the MBI-C-Total and subdomains—specifically Interest, Mood, and Control—were linked to increased likelihood of MCI. The robust association between mood disturbances and cognitive impairment is particularly compelling, as mood symptoms often precede CD and reflect underlying disruptions in neural circuits involved in emotional regulation(54,55). Interestingly, lower DASS Stress scores were inversely associated with cognitive impairment, possibly because moderate stress enhances attention and memory, consistent with the Yerkes-Dodson law(56). Collectively, these findings underscore that behavioral and mood-related symptoms may not only serve as early predictors but also actively contribute to the acceleration of CD. This assertion is well-supported by prior research on the prodromal stages of AD, which suggests early NPS play a significant role in modulating the disease's trajectory(57–59).

Behavioural-Biomarkers as Early Indicators of Neurodegeneration

Higher MBI-C scores were significantly associated with elevated A β 42 levels, particularly within the subdomains of Interest, Mood, and Control, supporting the role of early behavioral disturbances as clinical indicators of amyloid-related pathology(12,44,60,61). Moreover, higher DASS-Stress scores were strongly associated with elevated A β 40 levels, reinforcing evidence of an association between stress and amyloid pathology(62,63). The inconsistent findings for A β 42 and the A β 42/A β 40 ratio in our study and throughout literature highlight variability likely attributable to differences in study cohorts and methodological heterogeneity, underscoring the complexity of utilizing amyloid biomarkers for prediction of CD.

Furthermore, elevated MBI-C Total scores, DASS-Depression and DASS-Stress scores were significantly linked to higher p-tau181 levels, aligning with emerging evidence that behavioral

symptoms may correlate with tau pathology(12–14,64,65). This relationship illustrates the potential interplay between stress, depression, and tau-related neurodegeneration, which is critical for understanding the broader neuropathological mechanisms underlying CD. Finally, the marginal association between elevated GFAP levels and DASS-Anxiety scores suggests a tentative link between anxiety and neuroinflammatory processes, potentially reflecting glial activation in response to chronic psychological distress.

Plasma Biomarkers and MCI status

Our results demonstrate the potential of BBM to distinguish MCI from CN participants, reinforcing their value in early detection of AD and related cognitive disorders.

Amyloid Pathology and Early Detection

Although the A β 42/40 ratio did not significantly differ between the CN and MCI groups, the elevated A β 40 levels in MCI participants suggest early amyloid dysregulation. A β 40, which is increasingly implicated in amyloid plaque formation and neurotoxicity, may serve as an early biomarker of amyloid pathology despite historically receiving less attention than A β 42(66). This pattern aligns with recent research indicating that A β 40 elevations may precede A β 42 changes(67), supporting its potential as an early biomarker of amyloid-related pathology.

Tau

In contrast, p-tau181 did not differ significantly between cognitive groups nor predict MCI status. Although tau pathology is central to AD, plasma p-tau181 may have lower sensitivity to early cognitive impairment compared to markers of amyloid dysregulation or neuroinflammation(68). This corresponds with recent findings that p-tau181 becomes more relevant in later AD stages as tau pathology accumulates in the medial temporal cortex and spreads to other cortical regions(69,70).

Neurodegeneration

NfL emerged as a robust marker of neurodegeneration, strongly associated with MCI status. Its high sensitivity to axonal damage makes it valuable for detecting preclinical neurodegeneration and tracking the MCI-to-AD transition(71–73). This study supports NfL's role as a core biomarker for monitoring disease progression and evaluating neuroprotective therapies(74).

Neuroinflammation

The significant elevation of GFAP levels in MCI participants reinforces its role as a biomarker of neuroinflammation, specifically astrocytic activation(75). Our results suggest that neuroinflammation, a key driver of AD pathology, may precede or exacerbate AD-related changes, contributing to CD via oxidative stress, cytokine release, and neuronal damage(76,77). Detecting neuroinflammation through GFAP may enable early intervention strategies aimed at modulating these pathways before significant neuronal loss occurs.

Enhanced Predictive Power through Integrated Models

Our results show that integrating BBMs with behavioral assessments provides a comprehensive view of early pathological changes in CD, offering insights beyond traditional cognition-based models. The combined model demonstrated notably superior discriminative power (MCI vs. CN) compared to models using behavioral or BBM alone, emphasizing the value of capturing both pathobiological changes and NPS. Notably, GFAP and MBI-C Mood emerged as the most robust predictors of MCI, supporting addressing both neuroinflammatory processes and mood-related symptoms in early detection strategies.

The Role of Neuroinflammation and Behavioral Changes

The prominent role of GFAP in our findings emphasizes neuroinflammation as a key process in early pathogenesis of AD and other dementias. Elevated GFAP levels, reflecting astrocytic activation, are increasingly recognized not only as markers of neurodegeneration but as contributors to disease progression via cytokine release and reactive gliosis, actively drive neuroinflammatory responses that exacerbate neuronal injury and accelerate CD(78,79). Consequently, GFAP emerges as a critical biomarker for early detection, particularly in individuals with subtle cognitive changes at high risk for progression.

The significant predictive value of MBI-C-Mood scores emphasizes the role of mood disturbances as early indicators of neurodegeneration. Rather than psychological consequences of cognitive impairment, mood disturbances may reflect underlying neuropathological changes(80–82). The association between elevated mood scores, p-tau181, and GFAP links emotional dysregulation to biological markers of neurodegeneration, particularly in the prefrontal cortex and hippocampus—regions vulnerable to early AD pathology(83). These findings affirm the interplay between mood disturbances and the biological processes driving CD.

Limitations

As with most studies, there are limitations. The exclusion of participants with severe psychiatric diseases may limit the generalizability of our findings, as this group could provide crucial insights into early cognitive changes. Importantly, severity of psychiatric symptoms is often used as a proxy for psychiatric disorders, potentially overlooking neurodegeneration underlying some NPS. The cross-sectional design further restricts our ability to infer causality or track changes over time. The relatively small sample size also limits statistical power and generalizability to larger populations. Future longitudinal studies, such as those planned within the expanded BIOCIS cohort, will be essential to validate these associations, elucidate temporal relationships between NPS, BBM and CD. Finally, translating these findings into clinical practice will require research focused on validating biomarker mechanisms, assessing predictive value for disease progression, and ensuring the scalability, cost-effectiveness, and accessibility of biomarker assays for real-world implementation.

Conclusions

This study accentuates the value of integrating biological markers with behavioural-biomarkers to deepen our understanding of early neurodegeneration and CD. Elevated GFAP and MBI-C Mood scores emerged as robust indicators of cognitive impairment, spotlighting the vital roles of neuroinflammation and mood disturbances. This integrative approach holds significant potential to enhance early detection of cognitive impairment, refine intervention strategies for at-risk populations, and improve outcomes through timely intervention.

The combination of self-reported MBI assessments with BBM provides enhanced diagnostic utility, enabling a more nuanced understanding of NDD progression. As precision medicine gains prominence, such integrative models can inform clinical decision-making and enable targeted disease-modifying therapies for individuals with neurodegenerative disorders. By establishing a framework that incorporates NPS, MBI, and BBM into diagnostic protocols, this research supports targeted therapeutic interventions and has the potential to transform dementia diagnosis, monitoring, and care.

List of abbreviations

NDD - Neurodegenerative Disease

CD - Cognitive Decline

BBM - Blood-Based Biomarkers

PET - Positron Emission Tomography

AD - Alzheimer's Disease

NPS - Neuropsychiatric Symptoms

MBI - Mild Behavioral Impairment

MBI-C - Mild Behavioral Impairment Checklist
DASS - Depression, Anxiety, and Stress Scales
CSF - Cerebrospinal Fluid
MCI - Mild Cognitive Impairment
ATN - Amyloid, Tau, and Neurodegeneration
A β 42 - Amyloid-Beta 42
A β 40 - Amyloid-Beta 40
p-tau181 - Phosphorylated Tau at position 181
NfL - Neurofilament Light
GFAP - Glial Fibrillary Acidic Protein
APOE4 - Apolipoprotein E ϵ 4
ADNI - Alzheimer's Disease Neuroimaging Initiative
BIOCIS - Biomarkers and Cognition Study, Singapore
CN - Cognitively Normal
NIA-AA - National Institute on Aging-Alzheimer's Association
EDTA - Ethylenediaminetetraacetic Acid
SNPs - Single Nucleotide Polymorphisms
PCR - Polymerase Chain Reaction
Simoa - Single Molecule Array
AUC - Area Under the Curve
ROC - Receiver Operating Characteristic

Article Information

Corresponding Author: Nagaendran Kandiah, Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Rd, Singapore 308232 (nagaendran_kandiah@ntu.edu.sg)

Author Contributions: Yi Jin Leow had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Yi Jin Leow

Acquisition, analysis, or interpretation of data: Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari, Gurveen Kaur Sandhu, Pricilia Tanoto, Faith Phemie Hui En Lee, Smriti Ghildiyal, Shan Yao Liew, Gursimar Bhalla, Sim Xin Ying, Adnan Azam Mohammed, Ashwati Vipin, Chao Dang, Nagaendran Kandiah

Drafting of the manuscript: Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari, Nagaendran Kandiah

Statistical analysis: Yi Jin Leow, Seyed Ehsan Saffari

Supervision: Nagaendran Kandiah

Funding: This study received funding support from the Strategic Academic Initiative grant from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Medical Research Council, Singapore under its Clinician Scientist Award (MOH-CSAINV18nov-0007); Ministry of Education, Singapore, Academic Research Fund Tier 1 (RT02/21); and Ministry of Education, Singapore, Science of Learning Grant (MOESOL2022-0002).

Conflict of Interest Disclosures: All authors declare no competing interests.

Acknowledgements: The authors express their gratitude to all individuals who are currently or will be participating in research at the Dementia Research Centre (Singapore).

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to ethical restrictions, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Informed consent was obtained from all participants according to the Declaration of Helsinki and local clinical research regulations, and procedures used in the study were in accordance with ethical guidelines. This study has been approved by the NTU Institutional Review Board (NTU-IRB-2021-1036), and procedures used in the study were in accordance with ethical guidelines.

Consent for publication

All authors have reviewed and approved the contents of the final manuscript contents and provided consent for its publication.

References

1. Mortby ME, Burns R, Eramudugolla R, Ismail Z, Anstey KJ. Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms. *Journal of Alzheimer's Disease*. 2017;59(1):141–53.
2. Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. *The American Journal of Geriatric Psychiatry*. 2019;27(8):823–34.

3. Ismail Z, McGirr A, Gill S, Hu S, Forkert ND, Smith EE. Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline. *Journal of Alzheimer's disease*. 2021;80(1):459–69.
4. McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms. *Neurology*. 2022;98(21):e2132–9.
5. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. *Journal of Alzheimer's disease*. 2017;56(3):929–38.
6. Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. *Alzheimer's & Dementia*. 2016;12(2):195–202.
7. Leow Y, Soo SA, Kumar D, Zailan FZB, Sandhu GK, Vipin A, et al. Mild Behavioral Impairment and Cerebrovascular Profiles Are Associated with Early Cognitive Impairment in a Community-Based Southeast Asian Cohort. *Journal of Alzheimer's Disease*. 2024;(Preprint):1–9.
8. Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic. *Journal of Alzheimer's Disease*. 2019;70(2):505–13.
9. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behaviour research and therapy*. 1995;33(3):335–43.
10. Freire ACC, Pondé MP, Liu A, Caron J. Anxiety and depression as longitudinal predictors of mild cognitive impairment in older adults. *The Canadian Journal of Psychiatry*. 2017;62(5):343–50.
11. Perin S, Lai J, Pase M, Bransby L, Buckley R, Yassi N, et al. Elucidating the association between depression, anxiety, and cognition in middle-aged adults: Application of dimensional and categorical approaches. *Journal of Affective Disorders*. 2022;296:559–66.
12. Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. *Molecular Neurodegeneration*. 2023;18(1):50.
13. Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z, et al. Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease. *Neurology*. 2023;100(7):e683–93.
14. Gonzalez-Bautista E, Momméja M, de Mauléon A, Ismail Z, Vellas B, Delrieu J, et al. Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia-free older adults. *Alzheimer's & Dementia*. 2024;
15. Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease. *Alzheimer's research & therapy*. 2022;14:1–5.
16. Gates N, Valenzuela M, Sachdev PS, Fiatarone Singh MA. Psychological well-being in individuals with mild cognitive impairment. *Clinical interventions in aging*. 2014;779–92.

17. Aye S, Handels R, Winblad B, Jönsson L. Optimising Alzheimer's disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment. *The Journal of Prevention of Alzheimer's Disease*. 2024;1–15.
18. Blennow K, Galasko D, Pernecky R, Quevenco F, van der Flier WM, Akinwonmi A, et al. The potential clinical value of plasma biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*. 2023;19(12):5805–16.
19. Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a clinical-biological construct—an International Working Group recommendation. *JAMA neurology*. 2024;
20. Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*. 2022;18(12):2669–86.
21. Kodosaki E, Zetterberg H, Heslegrave A. Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease. *Expert Review of Molecular Diagnostics*. 2023;23(12):1153–65.
22. Kivisäkk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse K, El-Mufti L, et al. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. *Frontiers in neurology*. 2023;14:1069411.
23. Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*. 2021;17(7):1145–56.
24. Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. *JAMA*. 2024;332(15):1245–57.
25. VandeVrede L, Rabinovici GD. Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care? *JAMA neurology*. 2024;81(10):1030–1.
26. Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical practice and trials. *Nature aging*. 2023;3(5):506–19.
27. Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma amyloid- β 42/40 for detecting Alzheimer disease amyloid plaques. *Neurology*. 2022;98(7):e688–99.
28. Ankeny SE, Bacci JR, Decourt B, Sabbagh MN, Mielke MM. Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications. *Neurology and Therapy*. 2024;1–17.
29. Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts. *Nature Communications*. 2023;14(1):6747.
30. Chen S, Huang Y, Shen X, Guo Y, Tan L, Dong Q. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. *Transl Psychiatry*. 2021; 11: 356. 2021;

31. Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Translational psychiatry*. 2021;11(1):27.
32. Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2024;10(3):e12490.
33. Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. *Brain*. 2023;146(2):690–9.
34. Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, et al. Apolipoprotein E ϵ 4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. *Dementia and geriatric cognitive disorders*. 2011;31(1):20–30.
35. Vipin A, Kumar D, Soo SA, Zailan FZ, Leow YJ, Koh CL, et al. APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia. *Alzheimer's Research & Therapy*. 2023;15(1):103.
36. EMA. Leqembi recommended for treatment of early Alzheimer's disease [Internet]. 2024. Available from: <https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease>
37. Qiu WQ, Zhu H, Dean M, Liu Z, Vu L, Fan G, et al. Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease. *International journal of geriatric psychiatry*. 2016;31(3):316–22.
38. Pomara N, Bruno D, Plaska CR, Ramos-Cejudo J, Osorio RS, Pillai A, et al. Plasma Amyloid- β dynamics in late-life major depression: a longitudinal study. *Translational Psychiatry*. 2022;12(1):301.
39. Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. *The American Journal of Geriatric Psychiatry*. 2010;18(11):973–82.
40. Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman A, Ikram MA, et al. Plasma amyloid β , depression, and dementia in community-dwelling elderly. *Journal of psychiatric research*. 2013;47(4):479–85.
41. Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, Algeciras-Schimnich A, Dage JL, et al. Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2023;15(3):e12461.
42. Huang L, Huang Q, Xie F, Guo Q. Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasma biomarkers. *Journal of Affective Disorders*. 2024;348:200–6.
43. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al. Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. *Journal of psychiatric research*. 2021;144:54–8.

44. Miao R, Chen HY, Gill S, Naude J, Smith EE, Ismail Z, et al. Plasma β -amyloid in mild behavioural impairment–neuropsychiatric symptoms on the Alzheimer’s continuum. *Journal of geriatric psychiatry and neurology*. 2022;35(3):434–41.
45. Naude JP, Gill S, Hu S, McGirr A, Forkert ND, Monchi O, et al. Plasma neurofilament light: a marker of neurodegeneration in mild behavioral impairment. *Journal of Alzheimer’s disease*. 2020;76(3):1017–27.
46. Petersen RC. Mild cognitive impairment as a diagnostic entity. *Journal of internal medicine*. 2004;256(3):183–94.
47. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. *Alzheimer’s & dementia*. 2018;14(4):535–62.
48. Leow Y, Wang J, Vipin A, Sandhu G, Soo S, Kumar D, et al. Biomarkers and Cognition Study, Singapore (BIOCIS): Protocol, Study Design, and Preliminary Findings. *The Journal of Prevention of Alzheimer’s Disease*. 2024;1–13.
49. Pendlebury ST, Poole D, Burgess A, Duerden J, Rothwell PM, Oxford Vascular Study. APOE- ϵ 4 genotype and dementia before and after transient ischemic attack and stroke: population-based cohort study. *Stroke*. 2020;51(3):751–8.
50. Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. *Molecular neurodegeneration*. 2016;11:1–8.
51. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. *Journal of laboratory automation*. 2016;21(4):533–47.
52. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clinical Cancer Research*. 2012;18(8):2290–300.
53. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). *Clinical Cancer Research*. 2013;19(24):6957–66.
54. Gao W, Yan X, Yuan J. Neural correlations between cognitive deficits and emotion regulation strategies: understanding emotion dysregulation in depression from the perspective of cognitive control and cognitive biases. *Psychoradiology*. 2022;2(3):86–99.
55. Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, et al. A cognitive biotype of depression and symptoms, behavior measures, neural circuits, and differential treatment outcomes: a Prespecified secondary analysis of a randomized clinical trial. *JAMA Network Open*. 2023;6(6):e2318411–e2318411.
56. Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. *Brain and cognition*. 2007;65(3):209–37.

57. Devanand DP, Lee S, Huey ED, Goldberg TE. Associations between neuropsychiatric symptoms and neuropathological diagnoses of Alzheimer disease and related dementias. *JAMA psychiatry*. 2022;79(4):359–67.
58. Dietlin S, Soto M, Kiyasova V, Pueyo M, de Mauleon A, Delrieu J, et al. Neuropsychiatric symptoms and risk of progression to Alzheimer’s disease among mild cognitive impairment subjects. *Journal of Alzheimer’s Disease*. 2019;70(1):25–34.
59. Guan DX, Rehman T, Nathan S, Durrani R, Potvin O, Duchesne S, et al. Neuropsychiatric symptoms: Risk factor or disease marker? A study of structural imaging biomarkers of Alzheimer’s disease and incident cognitive decline. *Human Brain Mapping*. 2024;45(13):e70016.
60. Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. *Alzheimer’s & dementia*. 2020;16(1):192–9.
61. Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, Vanelli F, et al. Neurodegeneration, β -amyloid and mood disorders: state of the art and future perspectives. *International journal of geriatric psychiatry*. 2013;28(7):661–71.
62. Brown RB. Stress, inflammation, depression, and dementia associated with phosphate toxicity. *Molecular Biology Reports*. 2020;47(12):9921–9.
63. Plascencia-Villa G, Perry G. Neuropathologic changes provide insights into key mechanisms of Alzheimer disease and related dementia. *The American Journal of Pathology*. 2022;192(10):1340–6.
64. Naude J, Wang M, Leon R, Smith E, Ismail Z. Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment. *Neurobiology of Aging*. 2024;138:19–27.
65. Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M, et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. *Alzheimer’s & Dementia: Translational Research & Clinical Interventions*. 2021;7(1):e12154.
66. Walsh DM, Selkoe DJ. Amyloid β -protein and beyond: the path forward in Alzheimer’s disease. *Current opinion in neurobiology*. 2020;61:116–24.
67. Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, et al. Elevation of the plasma A β 40/A β 42 ratio as a diagnostic marker of sporadic early-onset Alzheimer’s disease. *Journal of Alzheimer’s Disease*. 2015;48(4):1043–50.
68. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. *Nature medicine*. 2020;26(3):379–86.
69. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet Neurology*. 2020;19(5):422–33.

70. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. *JAMA neurology*. 2017;74(5):557–66.
71. Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. *Nature Reviews Neuroscience*. 2023;24(1):23–39.
72. Hawksworth J, Fernandez E, Gevaert K. A new generation of AD biomarkers: 2019 to 2021. *Ageing research reviews*. 2022;79:101654.
73. Simrén J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. *Advances in clinical chemistry*. 2023;112:249–81.
74. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nature medicine*. 2019;25(2):277–83.
75. Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlsson N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. *Alzheimer's research & therapy*. 2021;13:1–9.
76. Spotorno N, Najac C, Stomrud E, Mattsson-Carlsson N, Palmqvist S, Van Westen D, et al. Astrocytic function is associated with both amyloid- β and tau pathology in non-demented APOE ϵ 4 carriers. *Brain Communications*. 2022;4(3):fca135.
77. Pereira JB, Janelidze S, Smith R, Mattsson-Carlsson N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. *Brain*. 2021;144(11):3505–16.
78. Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM. Astrocytes in Alzheimer's disease: pathological significance and molecular pathways. *Cells*. 2021;10(3):540.
79. Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, et al. Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases. *Molecules*. 2022;27(10):3194.
80. Cozza M, Boccardi V. A narrative review on mild behavioural impairment: an exploration into its scientific perspectives. *Ageing clinical and experimental research*. 2023;35(9):1807–21.
81. Fisher DW, Dunn JT, Dong H. Distinguishing features of depression in dementia from primary psychiatric disease. *Discover Mental Health*. 2024;4(1):3.
82. Jack Jr CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia*. 2024;
83. Morella IM, Brambilla R, Morè L. Emerging roles of brain metabolism in cognitive impairment and neuropsychiatric disorders. *Neuroscience & Biobehavioral Reviews*. 2022;142:104892.